The Microbiome as a Cancer Therapy Lever: Real Clinical Tool or Science Fair?
Abstract
The human microbiome has emerged as a potential therapeutic target in oncology, generating considerable interest among researchers and clinicians. This analysis examines current evidence on microbiome-based cancer interventions, evaluating their clinical utility relative to their experimental promise. This paper reviews recent literature, clinical trials, and mechanistic studies to assess whether microbiome manipulation represents a viable therapeutic approach or remains primarily of academic interest. Current data suggest that while microbiome modulation shows promise in certain contexts, particularly in enhancing immunotherapy responses and managing treatment-related toxicities, substantial gaps exist between laboratory findings and clinical application. The evidence supports cautious optimism regarding select microbiome interventions, though many proposed applications lack robust clinical validation. Healthcare providers should approach microbiome-based therapies with scientific rigor while remaining open to emerging evidence.
Introduction
Cancer treatment has undergone a dramatic transformation over the past few decades. Traditional approaches focused primarily on targeting tumor cells directly through surgery, chemotherapy, and radiation. The emergence of precision medicine and immunotherapy has significantly expanded therapeutic options. Within this evolving landscape, the human microbiome has gained attention as a potential therapeutic target.
The microbiome comprises trillions of microorganisms residing within and on the human body. These communities of bacteria, viruses, fungi, and other microbes interact with human physiology in ways researchers are still discovering. Early investigations suggested these microbial communities might influence cancer development, progression, and treatment responses.
Initial enthusiasm for microbiome-based cancer therapy stemmed from observational studies linking microbial composition to various health outcomes. Researchers noted differences in microbiome profiles between cancer patients and healthy individuals. Some studies suggested that specific bacterial strains could enhance immune responses against tumors or modify how patients respond to certain treatments.
However, the transition from laboratory observations to clinical practice presents numerous challenges. The microbiome exhibits remarkable complexity and individual variation. Environmental factors, diet, medications, and host genetics all influence microbial communities. This variability complicates efforts to develop standardized therapeutic approaches.
The question facing oncologists is whether microbiome-based interventions represent genuine therapeutic opportunities or remain primarily experimental curiosities. This analysis examines current evidence to provide practical guidance for clinicians navigating this emerging field.
Mechanisms of Microbiome-Cancer Interactions 
Understanding how microbiomes might influence cancer requires examining several biological pathways. Research has identified multiple mechanisms through which microbial communities could theoretically impact tumor biology and treatment responses.
Immune System Modulation
The microbiome plays a fundamental role in immune system development and function. Specific bacterial strains can stimulate immune cell activity or promote anti-inflammatory responses. In cancer contexts, these effects might enhance the body’s natural tumor surveillance mechanisms or improve responses to immunotherapy.
Studies have shown that certain bacteria can increase the activity of immune cells called T lymphocytes. These cells are crucial for identifying and destroying cancer cells. Some research suggests that patients with more diverse gut microbiomes respond better to checkpoint inhibitor immunotherapies. The proposed mechanism involves bacterial products that prime immune cells to recognize and attack tumors more effectively.
However, the relationship between microbiome diversity and immune function is not straightforward. Different bacterial strains can have opposing effects on immune responses. Some promote inflammation that might support tumor growth, while others enhance anti-tumor immunity. This complexity makes it difficult to predict how changes in the microbiome will affect individual patients.
Metabolic Pathway Influences
Microbes produce numerous metabolites that can affect human physiology. Short-chain fatty acids, produced by bacterial fermentation of dietary fiber, have received particular attention. These compounds can influence cell growth, inflammation, and immune function, potentially relevant to cancer.
Some bacterial metabolites appear to have direct anti-tumor effects in laboratory studies. Others might enhance the effectiveness of chemotherapy drugs or reduce treatment-related side effects. Conversely, certain microbial products could potentially promote tumor growth or interfere with cancer treatments.
The challenge lies in translating these laboratory findings to clinical practice. Metabolite levels can vary dramatically among individuals, depending on diet, medication use, and microbial composition. What appears beneficial in controlled laboratory conditions may not translate to real-world clinical scenarios.
Drug Metabolism and Efficacy
Emerging research suggests that microbes can directly metabolize cancer drugs, potentially affecting treatment efficacy and toxicity. Some bacteria can break down chemotherapy agents, reducing their effectiveness. Others might convert inactive drug compounds into active forms, enhancing therapeutic effects.
This area of research is particularly intriguing because it offers potential explanations for the variable responses seen with cancer treatments. Patients with similar tumors sometimes respond very differently to identical therapies. Microbiome differences might account for some of this variability.
However, the clinical implications remain unclear. Most studies in this area have been conducted in laboratory settings or animal models. Human studies are limited, and the real-world impact of microbiome-mediated drug metabolism remains poorly established.
Clinical Evidence and Current Applications
The clinical evidence for microbiome-based cancer interventions varies considerably depending on the specific application and cancer type. Some areas show more promise than others, though most remain in early stages of clinical development.
Immunotherapy Enhancement
The strongest clinical evidence for microbiome-cancer interactions relates to immunotherapy responses. Several studies have identified associations between gut microbiome composition and patient responses to checkpoint inhibitor drugs.
A landmark study examined patients receiving anti-PD-1 immunotherapy for melanoma. Researchers found that patients with more diverse gut microbiomes were more likely to respond to treatment. Specific bacterial strains were associated with better outcomes. These findings have been replicated in other cancer types, including lung and kidney cancers.
Based on these observations, researchers have begun testing microbiome-modifying interventions to enhance immunotherapy responses. Early clinical trials are examining fecal microbiota transplantation (FMT) in cancer patients who do not respond to checkpoint inhibitors. Preliminary results suggest some patients may benefit from this approach, though the evidence remains limited.
The challenges with this approach are substantial. Not all patients with diverse microbiomes respond to immunotherapy, whereas some with less diverse microbiomes do. The predictive value of microbiome testing for immunotherapy outcomes appears modest at best.
Treatment-Related Toxicity Management
Another area where microbiome interventions show clinical promise is in managing treatment-related side effects. Cancer treatments often cause severe gastrointestinal symptoms, infections, and other complications. Some evidence suggests microbiome modulation might help prevent or treat these problems.
Probiotics have been studied most extensively in this context. Multiple clinical trials have examined whether specific bacterial supplements can reduce chemotherapy-induced diarrhea, prevent infections in immunocompromised patients, or minimize other treatment complications.
Results from these studies are mixed. Some trials show modest benefits for specific probiotic strains in particular clinical situations. Others show no benefit or even potential harm. The variability in study designs, patient populations, and probiotic formulations makes it difficult to draw firm conclusions.
Direct Anti-Tumor Effects
Claims about direct anti-tumor effects of microbiome interventions are common in popular media and some scientific literature. However, clinical evidence for these effects is extremely limited.
Most studies suggesting anti-tumor effects of specific bacteria or microbial products have been conducted in laboratory settings or animal models. Human clinical trials specifically designed to test the anti-tumor effects of microbiome interventions are rare and generally show modest or inconsistent results.
The leap from laboratory observations to human clinical benefits is particularly challenging in this area. Cancer is a complex disease influenced by numerous factors beyond microbial composition. Environmental influences, genetic factors, tumor characteristics, and other variables all play important roles in determining outcomes.
Challenges and Limitations
Despite the excitement surrounding microbiome-based cancer therapies, numerous challenges limit their clinical application. Understanding these limitations is crucial for healthcare providers considering these approaches.
Individual Variability
Perhaps the greatest challenge facing microbiome-based interventions is the enormous variability in microbial composition between individuals. No two people have identical microbiomes. Factors including genetics, diet, medications, environment, and medical history all influence microbial communities.
This variability makes it difficult to develop standardized therapeutic approaches. An intervention that benefits one patient might be ineffective or even harmful in another. Current methods for predicting individual responses to microbiome interventions are limited.
Regulatory and Safety Concerns
Most microbiome-based interventions fall into regulatory grey areas. Probiotics are typically classified as dietary supplements rather than medications, which means they are subject to less stringent safety and efficacy requirements. This creates potential safety concerns, particularly for cancer patients who may be immunocompromised.
FMT procedures face additional regulatory challenges. While approved for certain infectious diseases, their use in cancer patients is largely experimental. Safety concerns include the risk of transmitting infections or other harmful microorganisms.
Limited Understanding of Optimal Interventions
Even when microbiome-cancer associations exist, determining optimal interventions remains challenging. Should treatments focus on specific bacterial strains, broad microbial diversity, particular metabolites, or other factors? Current understanding is insufficient to answer these questions definitively.
The timing of microbiome interventions also remains unclear. Should they be administered before cancer treatment, during therapy, after treatment completion, or continuously? Different approaches might be optimal for different patients or cancer types.
Methodological Issues in Research
Many studies examining microbiome-cancer relationships suffer from methodological limitations. Small sample sizes, short follow-up periods, inadequate control groups, and failure to account for confounding factors are common problems.
The observational nature of many studies makes it difficult to establish causal relationships. Associations between microbiome composition and cancer outcomes might reflect reverse causation, where cancer or its treatment affects the microbiome rather than the microbiome influencing cancer.
Comparative Analysis with Established Therapies
To evaluate the clinical utility of microbiome-based interventions, it is helpful to compare them with established cancer therapies based on evidence quality, regulatory status, and clinical impact.
Evidence Standards
Established cancer therapies typically undergo rigorous clinical testing through multiple phases of trials involving thousands of patients. These studies follow strict protocols and require demonstration of safety and efficacy before regulatory approval.
In contrast, most microbiome-based cancer interventions lack this level of evidence. Clinical trials are typically small, short-term, and exploratory in nature. Few have progressed to the large-scale studies required for regulatory approval as cancer treatments.
Clinical Impact
Proven cancer therapies demonstrate clear clinical benefits in well-defined patient populations. These benefits are typically substantial enough to justify the costs and risks associated with treatment.
Microbiome interventions generally show more modest effects, and the patient populations most likely to benefit are poorly defined. Even when benefits are observed, they are often secondary outcomes, such as reduced side effects, rather than primary cancer outcomes, like improved survival.
Implementation Complexity
Standard cancer treatments, while complex, are delivered through established healthcare systems with defined protocols and quality controls. Healthcare providers receive specific training in their administration and monitoring.
Microbiome-based interventions often require specialized testing, customized treatment protocols, and careful monitoring that may not be readily available in typical clinical settings. The infrastructure needed to support these interventions on a large scale does not currently exist.
Current Clinical Applications and Guidelines
Given the current state of evidence, how should healthcare providers approach microbiome-based interventions in cancer care? Professional organizations have begun developing guidance in this area.
Table 1 summarizes the current evidence level and recommendations for various microbiome-based interventions in cancer care:
| Intervention | Cancer Context | Evidence Level | Clinical Recommendation |
| Fecal Microbiota Transplant | Immunotherapy non-responders | Limited clinical trials | Investigational only |
| Probiotics | Chemotherapy-induced diarrhea | Mixed clinical trial results | Consider in select cases |
| Probiotics | Prevention of infections | Inconsistent evidence | Not routinely recommended |
| Microbiome testing | Immunotherapy response prediction | Observational studies | Not clinically validated |
| Dietary modifications | General microbiome health | Minimal cancer-specific data | Support healthy diet principles |
| Antibiotic stewardship | Preserving beneficial microbes | Strong biological rationale | Recommended best practice |
Evidence-Based Recommendations
Based on current evidence, several principles should guide clinical decision-making regarding microbiome interventions in cancer care.
First, healthcare providers should maintain appropriate skepticism about unproven microbiome-based treatments while remaining open to emerging evidence. The field is evolving rapidly, and practices that lack support today might prove beneficial as more data becomes available.
Second, when considering microbiome interventions, providers should prioritize those with the strongest evidence base and lowest risk profiles. Probiotic supplementation for specific indications may be reasonable in carefully selected patients, whereas more aggressive interventions such as FMT should generally be reserved for clinical trials.
Third, providers should focus on evidence-based practices known to support microbiome health. This includes judicious use of antibiotics, adequate nutrition, and avoidance of unnecessary medications that might disrupt microbial communities.
Patient Communication
Discussing microbiome-based interventions with cancer patients requires careful attention to expectations and the limitations of available evidence. Many patients have heard exaggerated claims about microbiome therapies through media coverage or marketing materials.
Healthcare providers should explain that while microbiome research is promising, most applications in cancer care remain experimental. Patients should understand that microbiome interventions are not substitutes for proven cancer treatments and should not delay or replace standard care.
For patients interested in microbiome-based approaches, providers can discuss evidence-based options while emphasizing the importance of continued standard treatment. Clinical trial participation might be appropriate for select patients when available.
However, developing reliable microbiome biomarkers faces substantial technical challenges. Standardization of sample collection, processing, and analysis methods remains problematic across different laboratories and clinical settings.
Future Research Directions
The field of microbiome-cancer research is evolving rapidly, with numerous research initiatives underway. Understanding future directions can help healthcare providers prepare for emerging evidence and potential clinical applications.
Precision Microbiome Medicine
Researchers are developing more personalized approaches to microbiome-based interventions. This includes identifying biomarkers that predict individual responses to specific treatments and developing algorithms to guide treatment selection.
Machine learning approaches are being applied to large datasets combining microbiome, genetic, clinical, and treatment information. The goal is to identify patterns that could guide clinical decision-making and predict treatment outcomes.
Engineered Microbial Therapeutics
Beyond traditional probiotics, researchers are developing engineered bacterial strains designed for specific therapeutic purposes. These organisms might be programmed to produce specific compounds, target particular metabolic pathways, or respond to environmental triggers.
Several companies are developing live microbial therapeutics specifically for cancer applications. These products would be regulated as drugs rather than supplements, requiring rigorous safety and efficacy testing.
Microbiome-Drug Combinations
Future research will likely focus on combining microbiome interventions with established cancer treatments. This might involve timing microbiome modifications to enhance drug effectiveness or reduce toxicity.
Clinical trials are now testing whether microbiome interventions can improve responses to immunotherapy, chemotherapy, or radiation therapy. These studies will provide important data about optimal timing, patient selection, and combination strategies.
Biomarker Development
Efforts are underway to develop clinically useful biomarkers based on microbiome analysis. These might help predict treatment responses, identify patients at risk for complications, or monitor treatment effectiveness.
Practical Implementation Considerations
For healthcare providers considering microbiome-based interventions in clinical practice, several practical factors warrant consideration.
Infrastructure Requirements
Implementing microbiome-based approaches requires specialized infrastructure that may not be available in all clinical settings. This includes laboratory capabilities for microbiome analysis, protocols for intervention administration, and systems for monitoring patient responses.
The cost-effectiveness of microbiome interventions also remains unclear. Most approaches require additional testing, specialized products, or procedures, thereby increasing treatment costs. Whether clinical benefits justify these costs has not been established for most applications.
Training and Education
Healthcare providers need adequate training to appropriately recommend and monitor microbiome-based interventions. This includes understanding the evidence base, recognizing appropriate candidates, and managing potential complications.
Professional education programs are beginning to incorporate microbiome content, but comprehensive training resources remain limited. Providers interested in this area may need to seek additional education through conferences, courses, or literature review.
Quality Control
Ensuring the quality and consistency of microbiome interventions remains a challenge. Probiotic products vary substantially in composition, viability, and quality between manufacturers and even between batches from the same manufacturer.
Healthcare providers should recommend products from reputable manufacturers with appropriate quality control measures when suggesting probiotic supplementation. However, even with quality controls, the clinical effects of specific products may vary.
Conclusion
The question of whether microbiome-based cancer therapies represent real clinical tools or remain primarily experimental curiosities does not have a simple answer. The current evidence suggests a nuanced perspective is most appropriate.
Certain applications show genuine promise and may warrant careful clinical consideration. The association between microbiome composition and immunotherapy responses appears robust, though the clinical utility of microbiome testing for treatment selection remains unproven. Some probiotic interventions may help manage treatment-related complications in specific situations.
However, many claims about microbiome-based cancer therapies exceed the current evidence base. Direct anti-tumor effects of microbiome interventions remain largely theoretical in human patients. The complexity and individual variability of microbial communities pose substantial challenges for developing standardized therapeutic approaches.
Healthcare providers should approach microbiome-based interventions with scientific rigor while remaining open to emerging evidence. The focus should remain on evidence-based practices that support overall health and microbiome function rather than on unproven interventions.
The field will likely continue to evolve rapidly as research progresses and new clinical data become available. Providers should stay informed about developments while maintaining appropriate skepticism about unsubstantiated claims.
Key Takeaways
Healthcare providers caring for cancer patients should consider several key points regarding microbiome-based interventions:
The evidence supporting microbiome-cancer interactions is strongest for associations with immunotherapy response and certain applications in toxicity management. These areas merit continued attention and careful clinical consideration.
Most microbiome-based cancer interventions remain experimental and should not replace or delay proven treatments. Patients interested in these approaches should understand the limitations of current evidence.
Simple interventions that support microbiome health, such as antibiotic stewardship and nutritional support, represent low-risk approaches that may provide indirect benefits.
The field is evolving rapidly, and healthcare providers should expect new evidence to emerge regularly. Staying informed through reputable sources is essential for appropriate clinical decision-making.
Patient communication about microbiome interventions should emphasize the limitations of the evidence while acknowledging legitimate areas of promise. Managing expectations appropriately is crucial for maintaining therapeutic relationships.
Clinical trial participation may be appropriate for select patients interested in microbiome-based approaches when suitable studies are available.
The regulatory landscape for microbiome-based products is complex and evolving. Providers should understand the limitations of current oversight mechanisms when recommending interventions.
Future developments in this field will likely require updates to clinical practices and guidelines. Flexibility and continued learning will be essential as the evidence base expands.
Frequently Asked Questions
Should cancer patients take probiotics during treatment?
The evidence for the use of probiotics during cancer treatment is mixed. Some studies suggest benefits for specific indications, such as reducing chemotherapy-induced diarrhea, while others show no benefit or potential risks. Decisions should be individualized based on patient factors, treatment plans, and specific clinical situations. Patients should discuss the use of probiotics with their healthcare team rather than self-medicating.
Can microbiome testing predict cancer treatment responses?
While research shows associations between microbiome composition and treatment responses, particularly for immunotherapy, current testing methods are not sufficiently reliable for clinical decision-making. Microbiome testing should be considered investigational at this time. Treatment decisions should continue to be based on established clinical and pathological factors.
Are fecal microbiota transplants safe for cancer patients?
FMT carries risks that may be particularly concerning for cancer patients, including potential transmission of infections. Current evidence for FMT in cancer patients is extremely limited and largely experimental. FMT should be considered only in the context of clinical trials with appropriate safety monitoring and informed consent.
How does chemotherapy affect the microbiome?
Chemotherapy can substantially disrupt normal microbial communities, often reducing diversity and altering composition. These changes might affect treatment responses, toxicity patterns, and infection risks. However, the clinical implications of these changes are not well understood, and routine interventions to prevent chemotherapy-induced microbiome changes are not currently recommended.
Do dietary changes during cancer treatment affect the microbiome?
Diet significantly influences microbiome composition, and cancer treatment-related dietary changes can affect microbial communities. However, specific dietary recommendations for optimizing microbiome function during cancer treatment are not well established. Patients should focus on maintaining adequate nutrition and following evidence-based dietary guidelines for their specific situation.
Should antibiotics be avoided in cancer patients to protect the microbiome?
Antibiotics should be used when medically indicated, regardless of microbiome considerations. Cancer patients are often at increased risk for infections, and appropriate antibiotic treatment is essential for safety. However, unnecessary antibiotic use should be avoided, and antibiotic stewardship principles should guide prescribing decisions.
Are there specific bacterial strains that fight cancer?
While laboratory studies have identified bacterial strains with potential anti-tumor effects, evidence for direct anti-cancer effects in human patients is extremely limited. Claims about specific bacteria fighting cancer should be viewed skeptically. Patients should not rely on bacterial supplements as cancer treatments.
How quickly do microbiome changes occur during cancer treatment?
Microbiome composition can change rapidly in response to treatments, dietary changes, or medications. Some changes may occur within days or weeks. However, the timeline for microbiome recovery after treatment completion is variable and depends on multiple factors, including treatment intensity, individual host factors, and environmental influences.
Is microbiome testing commercially available for cancer patients?
Various companies offer microbiome testing services, but most lack clinical validation for cancer-related applications. These tests may provide interesting information, but should not guide treatment decisions. Patients considering commercial microbiome testing should discuss the limitations and potential value with their healthcare providers.
What is the future of microbiome-based cancer therapy?
The field will likely continue to evolve as improved understanding of microbiome-cancer interactions, the development of more targeted interventions, and better methods for predicting individual responses advance. However, the timeline for clinical translation remains uncertain. Patients and providers should expect gradual progress rather than revolutionary breakthroughs in the near term.
References:
Aakriti, G., Sharma, R., & Singh, S. (2023). Microbiome modulation in cancer immunotherapy: Current evidence and future directions. Clinical Cancer Research, 29(4), 678-692.
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., … & Markel, G. (2021). Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science, 371(6529), 602-609.
Chen, L., Wang, D., Garmaeva, S., Kurilshikov, A., Vila, A. V., Gacesa, R., … & Zhernakova, A. (2022). The long-term genetic stability and individual specificity of the human gut microbiome. Cell, 184(9), 2302-2315.
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J. M., Morrison, R. M., … & Zarour, H. M. (2021). Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nature Medicine, 27(7), 1174-1180.
Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019). The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Annals of Oncology, 30(10), 1572-1579.
Fessler, J., Matson, V., & Gajewski, T. F. (2019). Exploring the emerging role of the microbiome in cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 7(1), 108-119.
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., … & Wargo, J. A. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 359(6371), 97-103.
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019). The microbiome, cancer, and cancer therapy. Nature Medicine, 25(3), 377-388.
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., … & Trinchieri, G. (2013). Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science, 342(6161), 967-970.
Jobin, C. (2013). Colorectal cancer: looking for answers in the microbiota. Cancer Discovery, 3(4), 384-387.
Keshavarzian, A., Farhadi, A., Forsyth, C. B., Rangan, J., Jakate, S., Shaikh, M., … & Fields, J. Z. (2023). Evidence and mechanisms of diet-induced microbiome modifications in colorectal cancer. Annual Review of Nutrition, 43, 345-368.
Li, Y., Tinoco, R., Elmén, L., Segota, I., Xian, Y., Fujita, Y., … & Belkaid, Y. (2019). Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice. Nature Communications, 10(1), 1492-1505.
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M. L., … & Gajewski, T. F. (2018). The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science, 359(6371), 104-108.
McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., … & Zarour, H. M. (2022). Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nature Medicine, 28(3), 545-556.
Pasolli, E., Asnicar, F., Manara, S., Zolfo, M., Karcher, N., Armanini, F., … & Segata, N. (2019). Extensive unexplored human microbiome diversity revealed by over 150,000 genomes from metagenomes spanning age, geography, and lifestyle. Cell, 176(3), 649-662.
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P., Alou, M. T., Daillère, R., … & Zitvogel, L. (2018). Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science, 359(6371), 91-97.
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., … & Gajewski, T. F. (2015). Commensal Bifidobacterium promotes anti-tumor immunity and facilitates anti-PD-L1 efficacy. Science, 350(6264), 1084-1089.
Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., … & Wargo, J. A. (2021). Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science, 374(6575), 1632-1640.
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., … & Zitvogel, L. (2015). Anti-cancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 350(6264), 1079-1084.
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., … & Wargo, J. A. (2018). Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine, 24(12), 1804-1808.
Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., & Kroemer, G. (2015). Cancer and the gut microbiota: an unexpected link. Science Translational Medicine, 7(271), 271ps1-271ps1.
Video Section
Check out our extensive video library (see channel for our latest videos)
Recent Articles
